Daily Respiratory Research Analysis
Analyzed 211 papers and selected 3 impactful papers.
Summary
Analyzed 211 papers and selected 3 impactful articles.
Selected Articles
1. Immunogenicity and safety of co-administration of adjuvanted respiratory syncytial virus prefusion F protein vaccine with 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years: a randomized, non-inferiority trial.
In a multicenter phase III randomized, open-label non-inferiority trial (n=1112), co-administering adjuvanted RSVPreF3 with PCV20 in adults ≥60 years achieved non-inferior RSV-A/B neutralizing titers and opsonophagocytic titers for all 20 PCV20 serotypes versus sequential dosing. Safety and reactogenicity were similar, with mostly mild-to-moderate, short-duration adverse events and rare unrelated SAEs.
Impact: This trial directly informs vaccination logistics by demonstrating immunologic non-inferiority and acceptable safety of co-administering two key adult vaccines, potentially improving uptake and coverage.
Clinical Implications: Clinicians and programs can co-administer RSVPreF3 and PCV20 during a single visit in adults ≥60 years without compromising immunogenicity or safety, streamlining workflows and improving adherence.
Key Findings
- Co-administration achieved non-inferior RSV-A and RSV-B neutralizing antibody titers versus sequential administration.
- Opsonophagocytic titers for all 20 PCV20 serotypes met non-inferiority margins with co-administration.
- Safety/reactogenicity profiles were similar between groups; adverse events were mostly mild-to-moderate and short-lived, with rare unrelated serious adverse events.
Methodological Strengths
- Phase III, randomized, multicenter design with predefined non-inferiority margins.
- Comprehensive immunogenicity assessment including RSV-A/B neutralization and opsonophagocytic titers for 20 serotypes.
Limitations
- Open-label design may introduce expectation bias, though immunologic endpoints are objective.
- Short-term immunogenicity and safety; clinical effectiveness and durability were not evaluated.
Future Directions: Evaluate clinical effectiveness, durability of protection, and operational feasibility across seasons and co-administration with additional vaccines (e.g., influenza, COVID-19).
BACKGROUND: Respiratory syncytial virus (RSV) illness and pneumococcal disease present high disease burden and health risks to older adults. Vaccination against these two illnesses is a key strategy to reduce this burden, and co-administration of the two vaccines could enhance vaccine uptake. This study evaluated the immunogenicity, safety and reactogenicity of co-administration of adjuvanted RSV prefusion F protein vaccine (adjuvanted RSVPreF3) with 20-valent pneumococcal conjugate vaccine (PCV20) in adults aged ≥60 years. METHODS: This phase III, open-label, randomized, non-inferiority trial was conducted across 38 centers in Belgium, Poland, Spain and the United States. Participants (N=1112) were randomized 1:1 to receive adjuvanted RSVPreF3 vaccine and PCV20 vaccine either concomitantly (Co-Ad group) or one month apart (Control group). The primary objectives were to assess immunogenicity as measured by RSV-A and RSV-B neutralizing titers, and opsonophagocytic titers for the PCV20 serotypes. Safety and reactogenicity were assessed as secondary objectives. RESULTS: All primary immunogenicity objectives were met. The upper limit of the 95% confidence interval of the geometric mean titer ratios for RSV-A, RSV-B and all twenty PCV20 serotypes were within the pre-defined non-inferiority margins. Safety profiles were similar across both groups, with most adverse events being mild to moderate in severity and of short duration. Serious adverse events and potential immune-mediated diseases were rare and unrelated to vaccination. CONCLUSIONS: Co-administration of adjuvanted RSVPreF3 vaccine and PCV20 vaccine in older adults is immunologically non-inferior to their sequential administration, with an acceptable safety profile. These findings support co-administration as a strategy to enhance vaccine uptake.
2. Type I interferons induced upon respiratory viral infection impair lung metastatic initiation.
In preclinical metastasis models, RSV infection reduced lung metastatic seeding and early outgrowth via a type I interferon–mediated remodeling of the lung environment. Intranasal IFN-α phenocopied RSV’s anti-metastatic effect, and IFN-inducible Galectin-9 restricted seeding across cancer cell types, supported by scRNA-seq and in vivo/ex vivo validation.
Impact: This work uncovers a previously unappreciated anti-metastatic effect of respiratory virus–induced type I interferons, revealing actionable targets (IFN-α, Galectin-9) and a host-environment mechanism shaping lung metastasis.
Clinical Implications: Although preclinical, the findings support evaluating intranasal or perioperative IFN-α and Galectin-9–modulating strategies to reduce lung metastatic seeding risk, and inform timing considerations relative to respiratory infections.
Key Findings
- RSV infection reduces lung metastatic seeding and early metastatic growth in vivo.
- Intranasal recombinant IFN-α recapitulates the anti-metastatic effect of RSV infection.
- IFN-α upregulates Galectin-9 locally and systemically; Galectin-9 alone limits metastatic seeding across cancer cell types.
Methodological Strengths
- Multiple tumor models with in vivo and ex vivo validation of mechanistic pathways.
- Single-cell RNA sequencing resolving epithelial/endothelial–tumor interactions and IFN-responsive programs.
Limitations
- Preclinical models may not capture full human metastatic dynamics or infection heterogeneity.
- Safety/efficacy of IFN-α or Galectin-9 modulation for metastasis prevention in humans remains untested.
Future Directions: Test IFN-α or Galectin-9–targeted interventions perioperatively or during micrometastatic risk windows; investigate biomarker-guided timing relative to respiratory viral exposures.
Metastatic breast cancer accounts for 7% of cancer-related deaths, with the lungs being a common site of cancer spread. In parallel, lower respiratory tract infections, including those caused by respiratory syncytial virus (RSV), remain a common cause of morbidity and mortality worldwide. Acute viral respiratory infections induce marked changes in the lung. However, how these changes influence metastasis initiation and cancer progression remains unclear. Using breast cancer and other cancer cell types in an experimental lung metastasis model, we show that RSV infection impairs tumor cell seeding and early growth in the lung, resulting in fewer metastatic nodules. We demonstrate that restriction of metastatic spread is due to alterations in the lung environment mediated by RSV-induced type I interferons (IFNs). Consistent with this idea, intranasal administration of recombinant IFN-α is sufficient to recapitulate the anti-metastatic effect of RSV infection. Using single cell RNA sequencing supported by in vivo and ex vivo validation, we show that IFN-α influences interactions between epithelial/endothelial cells and cancer cells. Furthermore, both RSV infection and IFN-α administration trigger marked local and systemic upregulation of Galectin-9, an IFN-inducible protein associated with acute respiratory infection in humans. Treatment of cancer cells with Galectin-9 alone is sufficient to restrict metastatic seeding. Altogether, our results suggest that type I IFNs induced by respiratory virus infection render the lungs less permissive to cancer cell seeding and consequently interfere with the ability of tumor cells to successfully initiate metastatic colonization.
3. Interferon-γ selectively promotes survival of alveolar progenitor cells in a human lung organoid model.
This study establishes a primary adult human lung organoid that enables long-term expansion of human-specific alveolar progenitors and serum-free differentiation into AT1-like cells. Interferon-γ was cytotoxic to mature AT1-like cells but selectively promoted survival of alveolar progenitors via BIRC3, revealing context-dependent cytokine effects on regeneration. The platform supports mechanistic discovery and therapeutic strategy development for alveolar repair.
Impact: Introduces a human-specific alveolar organoid with a novel finding that IFN-γ differentially affects progenitors versus mature AT1-like cells through BIRC3, reframing how inflammatory cues may be leveraged for regeneration.
Clinical Implications: Therapeutic strategies for alveolar injury (e.g., acute respiratory distress syndrome and fibrotic lung diseases) may need to preserve or harness IFN-γ signaling in progenitors while protecting mature alveolar epithelium. Timing and dosing of anti-inflammatory therapies should consider progenitor-supportive effects.
Key Findings
- A primary adult human lung organoid supports long-term expansion of human-specific alveolar progenitors and serum-free differentiation into AT1-like cells.
- IFN-γ is cytotoxic to mature AT1-like cells but selectively promotes alveolar progenitor survival via BIRC3.
- The model enables mechanistic dissection of inflammation–regeneration crosstalk and discovery of strategies to enhance alveolar repair.
Methodological Strengths
- Use of primary adult human organoids enabling human-specific alveolar progenitor expansion and differentiation
- Mechanistic linkage of cytokine effect to BIRC3 with a reductionist, reproducible platform
Limitations
- In vitro organoid context lacks full immune, stromal, and vascular microenvironment
- No in vivo validation or clinical outcome data yet
Future Directions: Validate IFN-γ–BIRC3 effects in vivo; test timing/dose-modulated cytokine or pathway-targeted interventions; apply the platform to patient-derived disease organoids for precision regenerative strategies.
Disease of the lung alveoli is frequently associated with acute or chronic inflammation. At present, there are no effective therapies to support regeneration of the alveolar epithelium, and ongoing inflammation adds an additional layer of complexity to many lung diseases. Here, we describe a primary adult human organoid model for investigating how inflammation shapes alveolar regeneration. Unlike previous models, this system supports long-term expansion of newly identified human-specific alveolar progenitor cells and serum-free differentiation into alveolar type 1 (AT1)-like cells. Using this platform, we find that interferon-gamma (IFN-γ) exerts cytotoxic effects on mature AT1-like cells while promoting survival of alveolar progenitor cells mediated by BIRC3. This unexpected selective positive effect of IFN-γ on alveolar progenitors underscores the need for nuanced and context-dependent evaluation of the influence of pro-inflammatory cytokines on alveolar regeneration. Our organoid model provides a reductionist platform for mechanistic studies and discovery of strategies to enhance alveolar regeneration.